Drug Trial Radar · NCT06640647
Phase Ia Clinical Study of HDM1005 Injection
Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Mar 19, 2024
Primary completion
Aug 6, 2024
Study completion Sep 26, 2024
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase Ia clinical study. It is aimed to evaluate the safety, tolerability, PK and PD characteristics of HDM1005 injection in healthy adult subjects.
Conditions
- Obesity and Overweight
Interventions
HDM1005 injection or placeboDrug
HDM1005 injection or placebo isubcutaneous injection once
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety OutcomesTime frame: Signing informed until day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Anhui Medical University
Hefei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.